Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Oral microbiota of patients with nasopharyngeal carcinoma

PROVIDER: PRJNA721474 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14224900_1.fastq.gz	Fastqsanger.gz
	SRR14224900_2.fastq.gz	Fastqsanger.gz
	SRR14225000_1.fastq.gz	Fastqsanger.gz
	SRR14225000_2.fastq.gz	Fastqsanger.gz
	SRR14225100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 454

Similar Datasets

Project description:Longitudinal oral microbiome of patients with nasopharyngeal carcinoma

| PRJNA1194502 | ENA

microRNA profile of human nasopharyngeal tissues: nasopharyngeal carcinoma tissues vs. normal nasopharyngeal tissues

Project description:MicroRNAs are biomarkers of prognosis and survival for many types of cancer. We evaluated whether microRNAs can predict the survival and efficacy of concurrent chemotherapy in nasopharyngeal carcinoma (NPC) patients. We retrospectively analyzed microRNA expression in 312 paraffin-embedded NPC specimens and 18 normal nasopharyngeal tissues using microarray. We found Forty-one microRNAs are differentially expressed between NPC and normal tissues, and a five-microRNA signature can predict survival independent of stage. NPC patients with the low-risk microRNA signature have a favorable response to concurrent chemotherapy. microRNA profiling of nasopharyngeal carcinoma tissues vs. normal nasopharyngeal tissues 312 paraffin-embedded nasopharyngeal carcinoma tissues and 18 paraffin-embedded normal nasopharyngeal tissues

2012-06-30 | E-GEOD-32960 | biostudies-arrayexpress

serum microRNA profile of human nasopharyngeal carcinoma

Project description:To evaluate whether serum microRNAs can predict survival in nasopharyngeal carcinoma (NPC) patients, we analyzed the serum microRNA expression profiles in 8 NPC patients with shorter-survival time and 8 age- and gender-matched NPC patients with longer-survival time using microarray. We identified a four-microRNA signature can predict survival of NPC patients. 8 serum samples from nasopharyngeal carcinoma patients with shorter-survival time and 8 serum samples from nasopharyngeal carinoma patients with longer-survival time

2012-12-31 | E-GEOD-43160 | biostudies-arrayexpress

Plasma miRNA profiling of nasopahryngeal carcinoma patients

Project description:We performed miRNA microarray analysis to find differentially expressed miRNAs between nasopharyngeal carcinoma patients and normal control subjects In this study, 20 nasopharyngeal carcinoma patients and 10 normal control subjects were selected to collect plasma samples and perform miRNA microarray profiling

2013-07-02 | E-GEOD-48442 | biostudies-arrayexpress

Nasopharyngeal carcinoma patient samples: radio-sensitive samples vs. radio-resistant samples

Project description:Expression profiling of nasopharyngeal carcinoma patients comparing radio-sensitive samples with radio-resistant samples. Two condition-experiments, radio-sensitive and radio-resistant nasopharyngeal carcinoma patients. Biological replicates: 8 radio-sensitive, 12 radio-resistant, different donors in the same hospital. One patient per array.

2013-09-21 | E-GEOD-32389 | biostudies-arrayexpress

Plasma miRNA profiling of nasopahryngeal carcinoma patients

Project description:We performed miRNA microarray analysis to find differentially expressed miRNAs between nasopharyngeal carcinoma patients and normal control subjects

2013-07-02 | GSE48442 | GEO

Heterozygous p53-R280T mutation promotes proliferation of NPC cells through activating PI3K/Akt signaling pathway

Project description:Heterozygous p53-R280T mutations frequently occur in many nasopharyngeal carcinoma cell lines and nasopharyngeal carcinoma patients. However, the role of this mutation in the progression of nasopharyngeal carcinoma remains unclear. In this study, we successfully generated the tp53 knockout nasopharyngeal carcinoma (NPC) cells by CRISPR/Cas9-mediated genome editing and found that knockout of heterozygous tp53-R280T inhibited the proliferation of NPC cells significantly in vivo and in vitro. Mechanistic analyses indicated that heterozygous p53-R280T can activate the PI3K/Akt Signaling pathway in NPC cells. In conclusion, our findings provide a mechanistic insight into the role of heterozygous p53-R280T in NPC progression.

2019-07-21 | GSE130398 | GEO

Expression profiles of tRNA-derived small RNAs and their potential roles in primary nasopharyngeal carcinoma

Project description:Transfer-RNA-Derived Small RNA (tsRNA) is a novel class of short non-coding RNA including stress-induced tRNA fragments (tiRNA) and tRNA-derived fragments (tRF). Using RNA sequencing, we evaluated the tsRNA expression profiles in the fresh nasopharyngeal carcinoma tissue specimens (n = 4) and mucosal tissue specimens (n = 4) in patients’ primary nasopharyngeal carcinoma (P-NPC) and nasopharyngitis. Bioinformatics analyses indicated that tsRNAs were the important regulators and potential new biomarkers of P-NPC.

2022-01-11 | GSE159746 | GEO

Project description:Microbiota in Nasopharyngeal carcinoma tumour

| PRJNA781368 | ENA

Genome-wide expressing profiling of nasopharyngeal carcinoma primary tumors versus non-cancerous nasopharyngeal tissues.

Project description:To explore differentially expressed genes between nasopharyngeal carcinoma (NPC) primary tumors and non-cancerous nasopharyngeal tissues, 18 NPC tissue samples versus 18 control samples were utilized to perform genome-wide expressing profiling. Consequently, 2992 genes were found to be differentially expressed in NPC tissues relative to the control (FC>2, P<0.05). Among these 2992 genes, uPA was ranked as the top one in all upregulated genes sorted by ascending order of P-value. Moreover, expression of uPAR was also upregulated in NPC tissues with FC=3.34 and P=7.52M-CM-^W105. 18 nasopharyngeal carcinoma primary tumors and 18 non-cancerous nasopharyngeal tissues were used to perform genome-wide expressing profiling. The median ages of patients were 46 (range, 19-77) for NPC patients and 45 (range, 18-78) for the non-cancerous cohort. Almost one third of patients were female. All samples were collected before any anti-cancer treatment.

2014-01-05 | E-GEOD-53819 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data